Alcohol Intake, Cardiometabolic Risk, Fibrosis, and Gut Microbiota in Steatotic Liver Disease: A Population-Based Health Checkup StudyOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This population study examined how alcohol intake relates to cardiometabolic risk, liver fibrosis, and gut microbiota in steatotic liver disease (SLD). SLD subtypes MASLD, MetALD, and ALD were recently redefined by alcohol level. Researchers ran a cross-sectional analysis of a community health checkup. Liver fat and stiffness were measured by transient elastography. Gut microbiota were profiled by 16S rRNA sequencing, with alcohol treated as both a category and a continuous exposure.
Who was studied?
The cohort was 950 adults (402 men, mean age 52 years) from the 2018 Iwaki health checkup in Aomori, Japan. Fatty liver, defined as CAP at least 248 dB/m, was present in 310 participants (33 percent). Among them, 222 had MASLD, 41 had MetALD, and 23 had ALD. Mean alcohol intake rose from 3.0 g/day in MASLD to 74.3 g/day in ALD. Significant fibrosis (stiffness at least 7.0 kPa) affected 40 of the fatty-liver participants (12.9 percent).
What were the most important findings?
Higher alcohol intake was linked to elevated systolic and diastolic blood pressure, triglycerides, AST, and gamma-GTP, but inversely to insulin resistance (HOMA-IR), with no clear safe threshold. In multivariable analysis, body mass index was the only independent predictor of fibrosis (adjusted OR 1.22, 95 percent CI 1.11 to 1.35), while alcohol showed no independent association. Alcohol-related SLD showed a distinct dysbiosis: the SCFA producer Blautia was depleted and the oral-associated genus Gemella was enriched (FDR q less than 0.05) versus non-SLD controls.
What are the greatest implications of this study?
The results suggest that in early SLD, alcohol continuously worsens cardiometabolic risk while fibrosis is anchored more to obesity than to alcohol dose. The authors favor combining quantitative alcohol and BMI data for risk stratification. The Blautia-depletion and Gemella-enrichment pattern may be an early microbiome marker of alcohol-related liver disease. Limitations include the cross-sectional design, self-reported alcohol, genus-level 16S data, and a single Japanese region, so causation cannot be inferred.